TITLE:
Comparative efficacy between glimepiride and metformin in preventing progression of prediabetes to type 2 diabetes
AUTHORS:
Udaya M. Kabadi
KEYWORDS:
Type 2 Diabetes Pharmacotherapy; CVD/Lipids/Insulin Resistance; Prediabetes
JOURNAL NAME:
Journal of Diabetes Mellitus,
Vol.3 No.3,
July
22,
2013
ABSTRACT: Background: Several
recent studies have shown that treatment with therapeutic lifestyle changes,
and/or several drugs retard progression of prediabetes to type 2 diabetes.
However, none of these studies used a Sulfonylurea (SU), although in UKPDS, SUs
delayed the progression of hyperglycemia and several subjects would have been
categorized as having prediabetes by present diagnostic criteria. Thus, SUs may
have delayed the progression in this group as well. Objective: Therefore, we
examined comparative efficacy of glimepiride and metformin in progression
to diabetes in subjects with prediabetes. Methods: Twenty men and 18 women ages
28 - 81 years with prediabetes were followed for 5 - 9 years. Prediabetes was
diagnosed by impaired fasting glucose and HbA1Cbetween 5.7% - 6.4% with two consecutive determinations
as recommended by American Diabetes Association. Twenty obese subjects were
administered metformin 500 mg/day and 18 non obese subjects received glimepiride
0.5 mg/day, in addition to dietary and exercise counseling. Results: Mean
duration of follow up was 5.8 ± 0.2 years. Fasting Plasma Glucose (FPG) and HbA1Cdeclined to